BeStock  
Stocks › Biotechnology › SLS

Sellas Life Sciences SLS

US equityMarket cap rank #2495Biotechnology
$13.66 −$1.20 (-8.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $14.21 +4.03%
Open$14.98
Prev close$14.86
Day range$13.39 – $15.19
Volume15.48M
Market cap$2.78B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-39.3x
CheapRich

Near the bottom of its 5-year range · 8th percentile, 5-year average -8.2x

Price / book12.1x
CheapRich

Above its usual level · 73rd percentile, 5-year average 7.7x

#5014 of 5330 stocks by PB (1 = cheapest)

Price / sales1,602.3x
CheapRich

Near the top of its 5-year range · 91st percentile, 5-year average 346.8x

#5104 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-74x-45x-16x13xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$10.99
Price vs. fair value+24.3%Trading above the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 12.15 – 7.74 73% (pricier than usual) #5014 of 5330 (1 = cheapest)
PE -39.30 -62.70 -8.20 8% (cheaper than usual) –
PS 1,602.33 39.08 346.81 91% (pricier than usual) #5104 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on SLS.

Sign in to join the discussion.

Scroll to Top